Table 1 Patients’ characteristics according to baseline ALT levels
From: Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations
ALT < 11 IU/L | 11 IU/L ≤ ALT ≤ 40 IU/L | P value | |
|---|---|---|---|
Patients’ demographics | |||
Age (years ± SD) | 78.8 ± 9 | 74.8 ± 11.2 | 0.008 |
Gender – males (n (%)) | 39 (54.9) | 77 (47.8) | 0.32 |
Norton score (number, IQR) | 14.93 (13–17) | 16.06 (13.5–19) | 0.002 |
Background diagnoses (groups) | |||
Cancer (n (%)) | 20 (28.2) | 36 (22.4) | 0.34 |
Dementia (n (%)) | 3 (4.2) | 7 (4.3) | 0.96 |
Diabetes (n (%)) | 33 (46.5) | 49 (30) | 0.018 |
Cardiovascular (n (%)) | 54 (76.1) | 119 (73.9) | 0.73 |
Metabolic (n (%)) | 47 (66.2) | 92 (57.1) | 0.19 |
Neurologic (n (%)) | 17 (23.9) | 42 (26.1) | 0.73 |
Endocrine (n (%)) | 12 (16.9) | 21 (13.0) | 0.49 |
Medications (groups) | |||
Steroids (n (%)) | 17 (23.9) | 28 (17.4) | 0.24 |
Anticoagulation (n (%)) | 27 (38) | 34 (21.1) | 0.007 |
Inhalers/Inhalation (n (%)) | 46 (64.8) | 111 (68.9) | 0.53 |
Anti-diabetic (n (%)) | 28 (39.4) | 48 (29.8) | 0.15 |
Cardiovascular (n (%)) | 62 (87.3) | 133 (82.6) | 0.37 |
Metabolic (n (%)) | 17 (23.9) | 33 (20.5) | 0.56 |
Neurologic (n (%)) | 33 (46.5) | 62 (36.5) | 0.25 |
Laboratory parameters | |||
Albumin (g/dL ± SD) | 3.4 ± 0.45 | 3.7 ± 0.45 | < 0.001 |
Creatinine (mg/dL, (IQR)) | 1.32 (0.93–1.53) | 1.07 (0.68–1.29) | < 0.001 |
Clinical outcomes | |||
Mortality (n (%)) | 49 (69.0) | 55 (34.2) | < 0.001 |
Survival time – median (months) | 18.5 | Median not reached | |